• 1
    Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 12211231.
  • 2
    Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705714.
  • 3
    Deckelbaum RJ, Williams CL. Childhood obesity: the health issue. Obesity Res 2001; 9: 239S243S.
  • 4
    Kaufman F. Type 2 diabetes mellitus in children and youth; a new epidemic. J Pediatr Endocrinol Metab 2002; 15(Suppl 2): 737744.
  • 5
    Nanda K. Non-alcoholic steatohepatitis in children. Pediatr Transplant 2004; 8: 613618.
  • 6
    Schwimmer JB, Deutsch R, Rauch JB, Behling C, Newbury R, Lavine JE. Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease. J Pediatr 2003; 143: 500505.
  • 7
    Alter MJ. Prevention of spread of hepatitis C. HEPATOLOGY 2002; 36(5 Suppl. 1 ): S93S98.
  • 8
    Dore GJ, Law M, MacDonald M, Kaldor JM. Epidemiology of hepatitis C virus infection in Australia. J Clin Virol 2003; 26: 171184.
  • 9
    Finnerty B. A semiannual update of drug abuse patterns and trends in Los Angeles County, California. In: Epidemiologic trends in drug abuse, Volume II. Proceedings of the Community Epidemiology Work Group, December 2003. NIH Publication No. 04-5365. Bethesda, MD: National Institutes of Health, Department of Health and Human Services, 2004: 90108.
  • 10
    Murray KF, Richardson LP, Morishima C, Owens JW, Gretch DR. Prevalence of hepatitis C virus infection and risk factors in an incarcerated juvenile population: a pilot study. Pediatrics 2003; 111: 153157.
  • 11
    Ogilvie EL, Veit F, Crofts N, Thompson SC. Hepatitis infection among adolescents resident in Melbourne Juvenile Justice Centre: risk factors and challenges. J Adolescent Health 1999; 25: 4651.
  • 12
    Bair RM, Baillargeon JG, Kelly PJ, Lerand SJ, Williams JF, Lyerla R, et al. Prevalence and risk factors for hepatitis C virus infection among adolescents in detention. Arch Pediatr Adolesc Med 2005; 159: 10151018.
  • 13
    Strauss RS, Barlow SE, Dietz WH. Prevalence of abnormal serum aminotransferase values in overweight and obese adolescents. J Pediatr 2000; 136: 727733.
  • 14
    Kenny DT, Nelson P, Butler T, Lennings C, Allerton M, Champion U. Young People on Community Orders Health Survey: Key Findings Report. Sydney, Australia: University of Sydney, 2006. ISBN: 1 86487 8452.
  • 15
    Cole TJ, Bellizzi MC, Flegal KM, Dietz WH. Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ 2000; 320: 12401243.
  • 16
    National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004; 114: 555576.
  • 17
    American Academy of Pediatrics Committee on Nutrition: statement on cholesterol. Pediatrics 1992; 90: 469473.
  • 18
    Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002; 137: 110.
  • 19
    Expert Panel on Detection EaToHBCiA. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 24862497.
  • 20
    Hepatitis C virus infection. American Academy of Pediatrics. Committee on Infectious Diseases. Pediatrics 1998; 101: 481485.
  • 21
    Gessoni G, Manoni F. Prevalence of anti-hepatitis C virus antibodies among teenagers in the Venetian area: a seroepidemiological study. Eur J Med 1993; 2: 7982.
  • 22
    Jonas MM, Robertson LM, Middleman AB. Low prevalence of antibody to hepatitis C virus in an urban adolescent population. J Pediatr 1997; 131: 314316.
  • 23
    Weild AR, Gill ON, Bennett D, Livingstone SJ, Parry JV, Curran L. Prevalence of HIV, hepatitis B, and hepatitis C antibodies in prisoners in England and Wales: a national survey. Commun Dis Public Health 2000; 3: 121126.
  • 24
    Butler TG, Dolan KA, Ferson MJ, McGuinness LM, Brown PR, Robertson PW. Hepatitis B and C in New South Wales prisons: prevalence and risk factors. Med J Aust 1997; 166: 127130.
  • 25
    Harris R. Recidivism Among Victorian Juvenile Justice Clients 1997–2001. Victoria, Australia: Department of Human Services, 2001: 150.
  • 26
    Beck A, Shipley B. Special Report: Recidivism of Young Parolees. Bureau of Justice Statistics. Washington, DC: US Department of Justice, Office of Justice Programs, 1987.
  • 27
    Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000; 20: 116.
  • 28
    Stroffolini T, Lorenzoni U, Menniti-Ippolito F, Infantolino D, Chiaramonte M. Hepatitis C virus infection in spouses: sexual transmission or common exposure to the same risk factors? Am J Gastroenterol 2001; 96: 31383141.
    Direct Link:
  • 29
    Terrault NA. Sexual activity as a risk factor for hepatitis C. HEPATOLOGY 2002; 36(5 Suppl. 1 ): S99S105.
  • 30
    Vandelli C, Renzo F, Romano L, Tisminetzky S, De Palma M, Stroffolini T, et al. Lack of evidence of sexual transmission of hepatitis C among monogamous couples: results of a 10-year prospective follow-up study. Am J Gastroenterol 2004; 99: 855859.
    Direct Link:
  • 31
    Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 2006; 13: 3441.
  • 32
    Jauncey M, Micallef JM, Gilmour S, Amin J, White PA, Rawlinson W, et al. Clearance of hepatitis C virus after newly acquired infection in injecting drug users. J Infect Dis 2004; 190: 12701274.
  • 33
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975982.
  • 34
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958965.
  • 35
    Allen SA, Spaulding AC, Osei AM, Taylor LE, Cabral AM, Rich JD. Treatment of chronic hepatitis C in a state correctional facility. Ann Intern Med 2003; 138: 187190.
  • 36
    Jeffrey GP, MacQuillan G, Chua F, Galhenage S, Bull J, Young E, et al. Hepatitis C virus eradication in intravenous drug users maintained with subcutaneous naltrexone implants. HEPATOLOGY 2007; 45: 111117.
  • 37
    Bock HL, Loscher T, Scheiermann N, Baumgarten R, Wiese M, Dutz W, et al. Accelerated schedule for hepatitis B immunization. J Travel Med 1995; 2: 213217.
  • 38
    Marchou B, Picot N, Chavanet P, Auvergnat JC, Armengaud M, Devilliers P, et al. Three-week hepatitis B vaccination provides protective immunity. Vaccine 1993; 11: 13831385.
  • 39
    Rogers N, Lubman DI. An accelerated hepatitis B vaccination schedule for young drug users. Aust N Z J Public Health 2005; 29: 305307.
  • 40
    Wright NM, Campbell TL, Tompkins CN. Comparison of conventional and accelerated hepatitis B immunisation schedules for homeless drug users. Commun Dis Public Health 2002; 5: 324326.
  • 41
    Sasse E, Doumas, B. How to Define and Determine Reference Intervals in the Clinical Laboratory: Approved Guideline. Second Edition. Pennsylvania USA, 2000. National Committee on Clinical Laboratory Standards (NCCLS) Document C28–A2; 20: 136.
  • 42
    Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 2000; 342: 12661271.
  • 43
    Zanella A, Conte D, Prati D, Mozzi F, Capelli C, Zanuso F, et al. Hepatitis C virus RNA and liver histology in blood donors reactive to a single antigen by second-generation recombinant immunoblot assay. HEPATOLOGY 1995; 21: 913917.
  • 44
    Kariv R, Leshno M, Beth-Or A, Strul H, Blendis L, Kokia E, et al. Re-evaluation of serum alanine aminotransferase upper normal limit and its modulating factors in a large-scale population study. Liver Int 2006; 26: 445450.
  • 45
    Elinav E, Ben-Dov IZ, Ackerman E, Kiderman A, Glikberg F, Shapira Y, et al. Correlation between serum alanine aminotransferase activity and age: an inverted U curve pattern. Am J Gastroenterol 2005; 100: 22012204.
    Direct Link:
  • 46
    Suzuki A, Angulo P, Lymp J, St Sauver J, Muto A, Okada T, et al. Chronological development of elevated aminotransferases in a nonalcoholic population. HEPATOLOGY 2005; 41: 6471.
  • 47
    Daniel S, Ben-Menachem T, Vasudevan G, Ma CK, Blumenkehl M. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. Am J Gastroenterol 1999; 94: 30103014.
    Direct Link:
  • 48
    Hay JE, Czaja AJ, Rakela J, Ludwig J. The nature of unexplained chronic aminotransferase elevations of a mild to moderate degree in asymptomatic patients. HEPATOLOGY 1989; 9: 193197.
  • 49
    Quiros-Tejeira RE, Cope-Yokoyama S, Brown KD, Kitagawa S, Klish WJ, Finegold M. Clinical and histological characteristics of children with obesity-associated steatohepatitis. [Abstract] HEPATOLOGY 2003; 38(Suppl 1): 200A.